Matthew Schellenberg, DO
Hospice and Palliative Medicine · Murray, UTNPI 1386855021
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,464 and has fallen 98.9% since, to $15 in 2025.
Across 165 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$229
- GSK$217
- Lilly USA, LLC$195
- Amarin Pharma, Inc.$150
- Boehringer Ingelheim$130
- Johnson & Johnson$110
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,31799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $229 |
| GSK | 18 | $217 |
| Lilly USA, LLC | 18 | $195 |
| Amarin Pharma, Inc. | 10 | $150 |
| Boehringer Ingelheim | 10 | $130 |
| Johnson & Johnson | 7 | $110 |
| Astellas Pharma US Inc | 8 | $108 |
| Pfizer | 8 | $106 |
| E.r. Squibb & Sons, L.L.C. | 7 | $102 |
| AstraZeneca | 8 | $101 |
| Sanofi-aventis U.S. LLC | 7 | $95 |
| Novo Nordisk | 7 | $91 |
| AbbVie | 5 | $91 |
| Boston Scientific | 6 | $86 |
| Novartis | 5 | $79 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Insulet Corporation | 1 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Nevro Corp. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Mylan Specialty L.p. | 1 | $23 |
| Abbott | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Gilead | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Biogen | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
Too few hospice and palliative medicine providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $16,555 |
| XareltoRivaroxaban | 14 | $4,836 |
| TradjentaLinagliptin | 13 | $3,380 |
| EntrestoSacubitril/Valsartan | 13 | $3,095 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 16 | $1,554 |
| Vancomycin Hcl | 15 | $1,405 |
| Duloxetine Hcl | 30 | $1,066 |
| Atorvastatin Calcium | 63 | $1,021 |
| Levothyroxine Sodium | 86 | $972 |
| Methenamine Hippurate | 16 | $906 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $900 |
| Potassium Chloride | 55 | $888 |
| Insulin Glargine-Yfgn | 11 | $623 |
| Losartan Potassium | 42 | $555 |
| Quetiapine Fumarate | 57 | $513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $16,55541 claims |
| Johnson & JohnsonXarelto | $110 | $4,83614 claims |
| Boehringer IngelheimTradjenta | $130 | $3,38013 claims |
| NovartisEntresto | $79 | $3,09513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hospice and palliative medicine providers in Utahon file to place this against a meaningful peer group, so we don't.
Other hospice and palliative medicine in Murray
- Jamie RebmanMurray$305
- Jane MacphersonMurray$39
- Gary GarnerProvo$2K
- Jeffrey JacksonWest Jordan$2K
- Jeffrey BrobergProvo$761
- Anna BeckSalt Lake City$165
- Cari LowSalt Lake City$125
- Kathleen IrbySalt Lake City$30
- Scott FahrnerSalt Lake City$28
- Zachary EreksonSt George$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.